Industrial emulsifiers such as carboxymethylcellulose erode the gut's protective mucus layer and drive inflammation and metabolic disease.
Original statement
والآليات لم تعد سرّاً: المستحلبات الصناعية كالكاربوكسي ميثيل سلولوز تُمزّق طبقة المخاط الواقية للأمعاء (Chassaing 2015 Nature).
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Industrial emulsifiers such as carboxymethylcellulose erode the gut's protective mucus layer and drive inflammation and metabolic disease.
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (study selection and narrative are the archive's, not necessarily Elawady's)
- Origin
- https://eltayebat.com/rule/ultra-processed-foods/
- Attribution uncertainty
- The archive homepage states that the forbidden-food section is supported by research 'independently of Dr. Diaa's words'. No evidence was found that Elawady himself cited these studies.
- Claimed mechanism
Microbiota encroachment into mucus, low-grade inflammation.
- Claimed health effect
Colitis, metabolic syndrome, CVD, T2D.
- Population concerned
Humans (extrapolated from mice)
- Geographic restriction by Elawady
none found
Scientific assessment
Potentially true – Some evidence points in favour of the statement, but it is not sufficient for a clear judgement.
Certainty of evidence: low – Further research is likely to change the assessment considerably.
1. What was claimed?
Emulsifiers damage the gut barrier and cause disease.
2. What is demonstrably correct?
Chassaing 2015 (A-UPF-15): CMC and P80 induced low-grade inflammation, metabolic syndrome and colitis in susceptible mice; Chassaing 2022 (A-UPF-16): CMC altered human microbiota and metabolome and caused mild abdominal discomfort; Sellem 2023 (I-UPF-04) and Salame 2024 (I-UPF-05): emulsifier intakes associated with CVD and T2D.
3. What is wrong or exaggerated?
'Erodes the mucus layer' is shown in mice only: mucus thinning and microbiota encroachment occurred with 0.1-1.0% CMC/P80 for 12 weeks, and in germ-free mice emulsifiers did not reduce mucus thickness (A-UPF-15). The cohort associations (I-UPF-04; per-SD HRs 1.03-1.11 for some celluloses and mono-/diglycerides, several not significant after FDR correction, carrageenans and lecithins not associated) give weak, indirect support for the cardiometabolic part only and no data on mucus or inflammation. 'No longer mysterious' therefore overstates the evidence: the clear disease effects are in mice; the human trial was tiny and short with a high dose; human disease associations are small and observational.
4. What remains unclear?
Effects at typical dietary intakes in humans.
5. Which studies support it?
A-UPF-15, A-UPF-16, I-UPF-04, I-UPF-05.
6. Which studies contradict it?
None contradicting; limitations noted.
7. What applies to Germany and Europe?
EFSA has re-evaluated many emulsifiers; they remain authorised with conditions of use; regulators have not concluded on these newer findings in this review.
8. What is known about Egypt?
No Egypt-specific data.
9. What practical conclusion is appropriate?
Reasonable precaution; not proven harm.
Assessment details
- Rationale for certainty of evidence
Strong mouse experiments (2015); a small human feeding RCT (n=16, 11 days, 15 g/day CMC) showed microbiome and metabolome changes and mucus encroachment in 2 of 7 participants; NutriNet-Santé cohorts found small associations (HR ~1.03-1.11 per increment) of specific emulsifiers with CVD and T2D. No human evidence that usual intakes cause disease.
- Source quality
The archive generalises a mouse finding to humans ('mechanisms are no longer mysterious').
- Regional transferability
High for EU: CMC (E466) and other emulsifiers are authorised under Reg. 1333/2008.
- Individual exceptions
Not applicable.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
In mice, two common emulsifiers caused gut inflammation and metabolic problems. A very small human study found changes in gut bacteria with one emulsifier. Large French surveys found slightly more heart disease and diabetes among people consuming more of certain emulsifiers. This is a concern worth studying, not proof of harm at normal intakes.
Studies on this claim
Studies supporting the claim (4)
-
Emulsifiers and gut inflammation in mice
Chassaing B et al.. Nature 2015 · PMID 25731162 · DOI 10.1038/nature14232Animal studycited by the Tayebat archivefull text checked★ key studyTwo common emulsifiers caused gut inflammation and metabolic problems in mice.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Do emulsifiers promote gut inflammation and metabolic syndrome via microbiota?
- How was the study done?
Mouse experiments with emulsifiers, germ-free mice and faecal transplants.
- How many people, animals or samples were studied?
Not stated; Wild-type and colitis-prone mice
- What was actually found?
Emulsifiers induced low-grade inflammation and obesity/metabolic syndrome in wild-type mice and robust colitis in predisposed mice; microbiota encroachment; effects transferable via microbiota.
- How large was the observed effect?
Not applicable
- What do the results mean in everyday life?
Possible concern for humans, not proven.
- What are the study's limitations?
Mouse study only; doses of 0.1-1% in all food or water; the researchers knew which mice got which treatment; some groups very small; only two emulsifiers tested.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
Moderate.
- What can explicitly not be concluded from this study?
It cannot show that emulsifiers cause bowel inflammation or weight gain in humans, or at what human intake level any effect would occur.
-
Emulsifier CMC in a small human trial
Chassaing B et al.. Gastroenterology 2022 · PMID 34774538 · DOI 10.1053/j.gastro.2021.11.006Randomised controlled trialcited by the Tayebat archiveabstract only checkedSeven people eating CMC for 11 days had changes in gut bacteria and mild discomfort.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Does CMC affect the gut in healthy humans?
- How was the study done?
Double-blind controlled feeding study, 11 days.
- How many people, animals or samples were studied?
16 (9 control, 7 CMC); Healthy adults
- What was actually found?
CMC modestly increased postprandial abdominal discomfort, reduced microbiota diversity, reduced faecal SCFAs and free amino acids; 2 CMC subjects showed microbiota encroachment into inner mucus.
- How large was the observed effect?
Not applicable
- What do the results mean in everyday life?
Early human signal.
- What are the study's limitations?
Very small; Short; High dose; Surrogate outcomes
- What does it say about Elawady's specific claim?
Supports C-UPF-06.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Disease risk.
-
Emulsifiers and heart disease in France
Sellem L et al.. BMJ 2023 · PMID 37673430 · DOI 10.1136/bmj-2023-076058Cohort studyindependent cross-checkfull text checked★ key studyHigher intake of some emulsifiers, including CMC, was linked with slightly more heart disease.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Are emulsifier intakes associated with CVD?
- How was the study done?
Prospective cohort with additive exposure estimation.
- How many people, animals or samples were studied?
95,442; 1,995 CVD events; Adults without CVD, 79% women
- What was actually found?
Celluloses (E460-E468) CVD HR 1.05 (1.02-1.09), CHD 1.07; CMC (E466) CVD 1.03 (1.01-1.05), CHD 1.04; E471/E472 associated with all outcomes; E472b cerebrovascular 1.11; trisodium phosphate CHD 1.06.
- How large was the observed effect?
HR 1.03-1.11 per SD
- What do the results mean in everyday life?
Small possible effect.
- What are the study's limitations?
One French cohort of mostly women volunteers; associations are very small and some disappear after correction for multiple testing; most emulsifiers studied showed no link; additive intake was estimated, not measured in blood or urine.
- What does it say about Elawady's specific claim?
Supports C-UPF-06 weakly.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
It cannot show that emulsifiers cause heart disease, nor that they erode the gut mucus in people; it does not provide absolute risks.
-
Emulsifiers and diabetes in France
Salame C et al.. Lancet Diabetes Endocrinol 2024 · PMID 38663950 · DOI 10.1016/S2213-8587(24)00086-XCohort studyindependent cross-checkabstract only checkedSeveral emulsifiers were linked with slightly higher diabetes risk.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Are emulsifiers associated with T2D?
- How was the study done?
Prospective cohort with time-dependent additive exposure.
- How many people, animals or samples were studied?
104,139; 1,056 T2D cases; Adults, 79% women
- What was actually found?
Carrageenans HR 1.03 per 100 mg/day; tripotassium phosphate 1.15 per 500 mg/day; E472e 1.04; sodium citrate 1.04; guar gum 1.11; gum arabic 1.03; xanthan gum 1.08.
- How large was the observed effect?
HR 1.03-1.15 per increment
- What do the results mean in everyday life?
Small possible effect.
- What are the study's limitations?
Single cohort; Multiple testing; Observational design; residual confounding possible; Self-reported dietary intake
- What does it say about Elawady's specific claim?
Supports C-UPF-06 weakly.
- Do the results apply to Germany and Europe?
High.
- What can explicitly not be concluded from this study?
Causation.
No study in this group is marked as key.
Studies contradicting or limiting the claim (0)
No studies in this group.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
EFSA has re-evaluated many emulsifiers; they remain authorised with conditions of use; regulators have not concluded on these newer findings in this review.
Egypt
No Egypt-specific data.
What applies in my country?
General scientific assessment
Potentially true Emulsifier harm is plausible and supported in animals, but human evidence is limited.
The following areas of food safety are relevant to this statement:
- Additives and processing
- Controls, imports, recalls, labelling
Choose a country to see the checked information for it.
Limits: legal rules describe what is allowed, not what every single food contains. Measurement data come from samples and are meaningful only together with their method details.
Country of residence or purchase Compare with another country
References
- Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome.. Chassaing B et al.. Nature 2015 · PMID 25731162 · DOI 10.1038/nature14232
- Randomized Controlled-Feeding Study of Dietary Emulsifier Carboxymethylcellulose Reveals Detrimental Impacts on the Gut Microbiota and Metabolome.. Chassaing B et al.. Gastroenterology 2022 · PMID 34774538 · DOI 10.1053/j.gastro.2021.11.006
- Food additive emulsifiers and risk of cardiovascular disease in the NutriNet-Santé cohort: prospective cohort study.. Sellem L et al.. BMJ 2023 · PMID 37673430 · DOI 10.1136/bmj-2023-076058
- Food additive emulsifiers and the risk of type 2 diabetes: analysis of data from the NutriNet-Santé prospective cohort study.. Salame C et al.. Lancet Diabetes Endocrinol 2024 · PMID 38663950 · DOI 10.1016/S2213-8587(24)00086-X